Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Non-Current Deffered Revenue (2017 - 2025)

Arcus Biosciences has reported Non-Current Deffered Revenue over the past 9 years, most recently at $43.0 million for Q4 2025.

  • Quarterly results put Non-Current Deffered Revenue at $43.0 million for Q4 2025, down 81.62% from a year ago — trailing twelve months through Dec 2025 was $43.0 million (down 81.62% YoY), and the annual figure for FY2025 was $43.0 million, down 81.62%.
  • Non-Current Deffered Revenue for Q4 2025 was $43.0 million at Arcus Biosciences, down from $53.0 million in the prior quarter.
  • Over the last five years, Non-Current Deffered Revenue for RCUS hit a ceiling of $462.0 million in Q4 2021 and a floor of $43.0 million in Q4 2025.
  • Median Non-Current Deffered Revenue over the past 5 years was $265.5 million (2024), compared with a mean of $252.2 million.
  • Biggest five-year swings in Non-Current Deffered Revenue: surged 3057.91% in 2021 and later crashed 81.66% in 2025.
  • Arcus Biosciences' Non-Current Deffered Revenue stood at $462.0 million in 2021, then fell by 23.16% to $355.0 million in 2022, then fell by 13.52% to $307.0 million in 2023, then fell by 23.78% to $234.0 million in 2024, then crashed by 81.62% to $43.0 million in 2025.
  • The last three reported values for Non-Current Deffered Revenue were $43.0 million (Q4 2025), $53.0 million (Q3 2025), and $60.0 million (Q2 2025) per Business Quant data.